Tora

Tora Biosciences is a pre-clinical stage biotechnology company focused on developing novel small molecule therapeutics for lysosomal storage disorders and neurodegenerative diseases. The company's primary focus is on modulating acid sphingomyelinase (ASM) activity to address the underlying pathology of Acid Sphingomyelinase Deficiency (ASMD), also known as Niemann-Pick disease. By leveraging deep expertise in lipid metabolism and lysosomal biology, Tora Biosciences aims to create disease-modifying treatments that can cross the blood-brain barrier to treat the neurological manifestations of these conditions. The company is currently advancing its lead programs through lead optimization and IND-enabling studies.